Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over £2m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR).

Red background with white pills spread around

The IOI Synergy Grants scheme is an internal Oxford-wide funding call for AMR-focused research with translational potential and with a strong focus on collaboration across university departments and disciplines.

Each project will receive funding of up to £500,000 over a two-year period. Projects include new antibiotic drug discovery, development of diagnostic tools to accurately diagnose infections, phages to kill drug-resistant bacteria, and behavior change interventions to reduce antibiotic usage.

Professor Sir Stewart Cole, Executive Chair of the IOI:

"AMR is a multi-faceted problem that cannot be solved by working in silos. Experts from medical sciences, life sciences and social sciences must work in unison to protect the existing antibiotics and find new ones. The IOI Synergy Grants bring together Oxford’s world-class researchers in an integrated multidisciplinary approach to shape the future of modern medicine.  

The projects exemplify the tremendous range of AMR research across the university, from new diagnostic tools to patient-facing interventions. The quality of research is outstanding, and I look forward to seeing real-world applications arise from the IOI Synergy initiative."

 

Read the full story on the Ineos Oxford Institute website.